Travelling activity and travel-related risks after allogeneic haematopoietic stem cell transplantation – a single centre survey

Travelling activity and travel-related risks after allogeneic haematopoietic stem cell transplantation – a single centre survey

Blog Article

BACKGROUND: Travel activity and travel-related risks of patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT) remain largely unknown.The aim of our study was to examine travel activity after allo-HSCT including travel behaviour and travel patterns.METHODS: We analysed travel characteristics of allo-HSCT recipients by using a retrospective cross-sectional survey.Allo-HSCT patients were asked to complete a questionnaire during their annual health visits from 2010 to 2012.RESULTS: Overall, 118/153 (77%) participating patients reported travel activity for a total of 201 travelling episodes.

Travellers versus non-travellers were receiving immunosuppressive treatment in 35.6% versus 65.7% (p = 0.002), and Spawn had graft-versus-host-disease (GvHD) in 52.5% versus 62.

9% (p Collections = 0.17).In a multivariate analysis, the time between the transplantation and the survey was the only factor associated with travel activity (p <0.0001) and taking pretravel advice (p <0.0001).

In 34.8% of travel episodes pretravel advice was sought.Patients with pretravel advice reported travel-related symptoms more frequently.Minor respiratory (27/201) and gastrointestinal (23/201) symptoms were most frequently indicated.Four percent (8/201) of the patients were hospitalised while travelling.

CONCLUSION: We conclude that travelling after allo-HSCT is frequent and linked to the time since transplantation.We could not define specific risks for any destination.Nevertheless, pretravel advice and preparation are highly recommended for immunosuppressed patients.